Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Repros Therapeutics (NasdaqGM:RPRX) today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program. Full Article at TransWorldNews